With recent disruptive pricing in the HCV market, will lower cost therapies take share from legacy treatments? Preview what payers forecast back in the second half of 2016 with our M Tracker data. Will their prediction become reality? Be on the lookout for the full report in the near future!

Click HERE to see full size image